MA-ANTERRA-CAPITAL
18.5.2022 07:02:06 CEST | Business Wire | Press release
A crushing pandemic and, more recently, the Ukraine war have convinced investors more than ever that the world needs to radically change how it produces, distributes and consumes food, says Adam Anders, managing partner of the international food and agriculture specialist venture capital firm Anterra Capital (“Anterra”).
Anders: “The pandemic highlighted the fragility and adverse health impacts of our current food system: soaring prices, empty shelves in stores; the fact that unhealthy diets are a major risk factor for getting Covid; that the way we treat farm animals could trigger the next pandemic. Post our final closing, the devastating impact of the Ukraine War on the global food supply has increased the awareness among investors even further. This, plus our focus on deploying proven biotech and digital solutions to shake up the lagging Food and Ag-sector, go a long way in explaining the higher than expected interest in our second fund.”
Anterra is proud to announce the closing of its second fund, with commitments in excess of $260 million. All investors from Anterra’s first fund returned in Fund II, led by Rabo Investments and Eight Roads Ventures. This fund also welcomes an international influx of new investors, ranging from pension funds and sovereign wealth funds to family offices and tech entrepreneurs from other sectors.
Anders: ”A new crop of mainstream investors is ready to get involved. Many already believed that the advances of the Green Revolution came at a hefty price. It gave us cheap fertilizer and powerful pesticides for growing plants; and growth hormones and antibiotics in animal production. But its obsession with yield is also destroying ecosystems and our own health. The pandemic gave the final push. Investors realize they can help build a resilient and regenerative food system and make excellent returns at the same time.”
One other unexpected outcome of the pandemic is that it has changed the outlook for using biotech in food and ag. Traditionally, this has been met with substantial public resistance. But since the roll-out of mRNA vaccines, billions of people have witnessed the positive power of biotech firsthand.
Anders: “Growing public acceptance of biotech solutions and gene-editing thanks to mRNA-vaccines, is an important shift. Biotech advances will also play a critical role in making food and agriculture more resilient and less carbon intensive; from fighting and preventing infectious diseases that jump from animals to humans; to developing more sustainable crop health solutions.”
Anterra believes that biotech and digital solutions are the two key technologies that will transform the food and agricultural sector. Through this technological lens Anterra seeks out entrepreneurs across the value-chain, ranging from ag fintech, crop science and animal health to human nutrition and consumer tech. Where it feels opportunities are being missed, Anterra also incubates companies itself: since 2018, Anterra has built five successful start-ups from scratch. At the same time, technology does not have to be cutting-edge to make its mark in the sector.
Anders: “Technology-wise food and ag lags 20 years behind sectors like human health and banking, so you don’t necessarily need the latest, cutting edge technology to transform it. Our incubated companies focus on deploying biotech and digital solutions that are established elsewhere, but are new to food and ag. I can confidently say we are unique in that approach. It’s an advantage of operating in a slow-moving sector: you can innovate in a slightly de-risked way.”
Executing this strategy, Anterra has built a diverse portfolio of innovators, ranging from entrepreneurs developing the next generation of targeted pesticides with low environmental impact, like Enko and Vestaron; start-ups improving animal and human health, like Invetx, Animol and Caribou Biosciences (co-founded by Nobel-prize winner Jennifer Doudna); companies empowering farmers with field data, access to finance, transparent pricing and direct distribution channels, like ProducePay and Agriconomie; and consumer tech-driven businesses transforming how we choose, buy and think about food, like LaFourche and Lollipop.
Anders: “Our strategy and years of experience are paying off. We look forward to supporting the next generation of great entrepreneurs and building a better food system.”
About Anterra
With offices in Amsterdam and Boston, Anterra Capital is an international specialist venture capital investor dedicated to financing the growth of technology-driven companies with incredible potential in food, agriculture, and animal health. Supported by multinational institutional investors, family offices and like-minded entrepreneurs, Anterra provides patient strategic capital to innovative companies sustainably transforming our global food system. Further information: www.anterracapital.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006310/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 22:08:00 CEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 21:00:00 CEST | Press release
Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, securi
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 16:30:00 CEST | Press release
Orchestration capabilities simplify workflows, while advanced agent connectivity and an enhanced context layer activate data and scale AI Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this visio
Boomi and Red Hat Collaborate on Production-Ready Agentic AI13.5.2026 16:30:00 CEST | Press release
Companies team to deliver a unified, enterprise-scale agentic stack to help organizations with managing data sovereignty and optimizing AI costs Boomi, the data activation company for AI, and Red Hat, the world’s leading provider of open source solutions, today announced a strategic collaboration to deliver a single, integrated stack for deploying agentic AI at scale. For many organizations, building production AI today means assembling numerous disconnected vendor choices spanning agent builders, orchestration tools, governance platforms, model providers, integration middleware, and security infrastructure, which can lead to data leaks and unpredictable costs. Boomi and Red Hat are working together to simplify AI innovation for customers by bringing together Boomi’s Agentstudio with the enterprise-grade power of Red Hat AI. This makes it easier for organizations to build agents that solve real business problems while supporting corporate standards for sovereignty, infrastructure flexi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
